Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
Recently, Aibo biology and Jiahe biology jointly announced that they have reached a cooperative development agreement. The two sides will jointly develop globally innovative mRNA products and related drugs. Based on the Jiahe biological antibody development platform and the mRNA technology platform of Aibo biology, the two sides will cooperate in the exploration and research of mRNA drugs for tumor treatment.
This is another important cooperation between Aibo biology and newforce after reaching a strategic partnership to jointly carry out the new drug research and development project of lipid nanoparticles (LNP) mRNA delivery for the treatment of retinal diseases, which further demonstrates the development strength of the platform company.
This text is a result of machine translation.
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
China's Road to Tackle Autoimmune Diseases Globally
The market of autoimmune diseases medication is vast both in China and overseas and presents great opportunities. However, the number of Chinese players specializing in autoimmune diseases is limited. This article introduced the autoimmune diseases medication market in China and explained why Chinese players are limited then give some recommendations on what efforts Chinese companies can make to compete with western players.
Oct 10, 2022 03:55 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Briefing Jun 23, 2022 10:20 AM
· Healthcare
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Insight
Healthcare
Challenges and Opportunities Possessed by Digital Therapeutics Industry
Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.
Nov 23, 2022 03:23 PM
Briefing Jun 23, 2022 10:15 AM
· Healthcare
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Briefing Jun 23, 2022 10:06 AM
· Healthcare
Mojia biology announced the completion of round B financing
Briefing Jun 23, 2022 09:50 AM
· Healthcare
First class recall of Draeger, a ventilator giant
Briefing Jun 22, 2022 02:30 PM
· Healthcare
The state plans to prohibit third-party platforms from directly participating in online drug sales
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth